Project Details
| Short title | JSKN003-101 |
|---|---|
| Acronym | JSKN003-101 |
| Status | Active |
| Effective start/end date | 22/11/22 → 21/11/27 |
CTU: A phase I, multi-centre, open-label, dose escalation, first in human study to assess the safety, tolerability and pharmacokinetics of JSKN003 in subjects with advance or metastatic solid malignant tumors
- Park, John (Primary Chief Investigator)
- Chester, Catherine (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research